Steve Davis, Acadia Pharmaceuticals CEO

FDA ad­vi­sors most­ly agree that Aca­dia’s Nu­plazid is­n't ef­fec­tive at treat­ing Alzheimer’s-re­lat­ed psy­chosis

A pan­el of the FDA’s out­side ex­perts vot­ed 9-3 that Aca­dia Phar­ma­ceu­ti­cals’ drug doesn’t ap­pear to be ef­fec­tive at treat­ing pa­tients with Alzheimer’s-re­lat­ed psy­chosis.

The drug, Nu­plazid, is al­ready in­di­cat­ed for Parkin­son’s-re­lat­ed psy­chosis, but Aca­dia has tried — and failed last year — to get an­oth­er green light in de­men­tia-re­lat­ed psy­chosis. The drug nev­er panned out in the clin­ic for pa­tients with de­pres­sion, caus­ing Aca­dia mul­ti­ple R&D headaches over the years.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.